Quinine sulfate


Questions | Reviews

quinine sulfate lawsuit


where can i find the information on the fda problems that are going on right now?And what exactly is going on?  
by patricia carter in usa, 07/13/2007

nocturnal leg cramps


Hi there, I suffer from leg and feet cramps periodically. My doctor prescribed Quinine Sulfate 200 mg. at bedtime. As I hate taking pills, I have only used them when I get the cramps and it's taken me almost two years to use 30. I always thought it wa...
by carol allan in Aurora, Ontario, Canada, 01/10/2006

Quinine Sulfate


Why was quinine sulfate taken off the market?  This medication works great for nocturnal leg cramps and has worked for me for years.  Now I am back to the cramps and trying various home remedies.  Can you tell me why it was taken off th...
by Linda in Alaska, 09/05/2007

Can drinking a lot of tonic water affect the muscles?


Can drinking too much tonic water cause muscluar weakness or disease?
by Tom Henderson in Honey Brook, PA, 07/07/2009

quinine sulfate has been taken off the market and I need replacement drug as I have s


Quinine sulfate has been taken off the market and I need a replacement drug. I have severe cramps in feet and legs at night.
by Dianna Bolster in Palm Bay, FL, 03/08/2007

View All 15 Questions

Quinine sulfate
Quinine sulfate (Formula Q, Legatrim)
Quinine sulfate
( KWYE-nine)
Pregnancy Category: X Formula Q Legatrim M-KYA Quinamm (Rx)

Classification: Antimalarial

Action/Kinetics: Natural alkaloid having antimalarial, antipyretic, analgesic, and oxytocic properties. Use in treating malaria is important due to emergence of resistant forms of vivax and falciparum; no resistant forms of the parasite have been found for quinine. Antimalarial mechanism not known precisely; quinine does affect DNA replication and may raise intracellular pH. Eradicates the erythrocytic stages of plasmodia. Increases the refractory period of skeletal muscle, decreases the excitability of the motor end-plate region, and affects the distribution of calcium within the muscle fiber, thus making it useful for nocturnal leg cramps. Is oxytocic and may cause congenital malformations. Rapidly and completely absorbed from the upper small intestine; widely distributed in body tissues. Peak plasma levels: 1-3 hr; plasma levels following chronic use: 7 mcg/mL. t 1/2: 4-5 hr. Highly bound to protein (70%-85%); about 5% excreted unchanged in urine. Small amounts found in saliva, bile, feces, and gastric juice. Acidifying the urine increases the rate of excretion.
Pharmacokinetics of quinine are affected by malaria, with a decrease in volume of distribution and systemic clearance. Protein binding, which is normally 70% to 85%, increases to more than 90% in clients with cerebral malaria, in pregnancy, and in children.

Uses: Alone or in combination with pyrimethamine and a sulfonamide or a tetracycline for resistant forms of Plasmodium falciparum. As alternative therapy for chloroquine, sensitive stains of P. falciparum, P. malariae, P. ovale and P. vivax. Mefloquine and clindamycin may also be used with quinine, depending on where the malaria was acquired. Investigational: Prevention and treatment of nocturnal recumbency leg cramps.

Contraindications: Use with tinnitus, G6PD deficiency, optic neuritis, history of blackwater fever, and thrombocytopenia purpura associated with previous use of quinine.

Special Concerns: Use with caution in clients with cardiac arrhythmias and during lactation. Hemolysis, with a potential for hemolytic anemia, may occur in clients with G6PD deficiency.

Side Effects: Use of quinine may result in a syndrome referred to as cinchonism. Mild cinchonism is characterized by tinnitus, headache, nausea, slight visual disturbances. Larger doses, however, may cause severe CNS, CV, GI, or dermatologic effects.
Allergic: Flushing, cutaneous rashes (papular, scarlatinal, urticarial), fever, facial edema, pruritus, dyspnea, tinnitus, sweating, asthmatic symptoms, visual impairment, gastric upset. GI: N&V, epigastric pain, hepatitis. Ophthalmologic: Blurred vision with scotomata, photophobia, diplopia, night blindness, decreased visual fields, impaired color vision and perception, amblyopia, mydriasis, optic atrophy. CNS: Headache, confusion, restlessness, vertigo, syncope, fever, apprehension, excitement, delirium, hypothermia, dizziness, convulsions. Otic: Tinnitus, deafness. Hematologic: Acute hemolysis, hemolytic anemia, thrombocytopenic purpura, agranulocytosis, hypoprothrombinemia. CV: Symptoms of angina, ventricular tachycardia, conduction disturbances, vasculitis. Miscellaneous: Sweating, hypoglycemia, lichenoid photosensitivity.

Overdose Management: Symptoms: Dizziness, intestinal cramping, skin rash, tinnitus. With higher doses, symptoms include apprehension, confusion, fever, headache, vomiting, and seizures. Treatment: Induce vomiting or undertake gastric lavage. Maintain BP and renal function. If necessary, provide artificial respiration. Sedatives, oxygen, and other supportive measures may be required. Give IV fluids to maintain fluid and electrolyte balance. Treat angioedema or asthma with epinephrine, corticosteroids, and antihistamines. Urinary acidification will hasten excretion; however, in the presence of hemoglobinuria, acidification of the urine will increase renal blockade.

Drug Interactions: Acetazolamide / Blood levels with potential for quinine toxicity R/T rate of elimination Aluminum-containing antacids / Or delayed quinine absorption Anticoagulants, oral / Additive hypoprothrombinemia R/T synthesis of vitamin K-dependent clotting factors Cimetidine / Quinine effect R/T rate of excretion Digoxin / Digoxin serum levels Heparin / Heparin effect Mefloquine / Risk of ECG abnormalities or cardiac arrest; also, risk of convulsions. Do not use together; delay mefloquine administration at least 12 hr after the last dose of quinine. Neuromuscular blocking agents (depolarizing and nondepolarizing) / Respiratory depression and apnea Rifabutin, Rifampin / Hepatic clearance of quinine; can persist for several days following discontinuation of the rifampin Sodium bicarbonate / Quinine blood levels with potential for quinine toxicity R/T elimination rate

How Supplied: Capsule: 180 mg, 200 mg, 324 mg, 325 mg; Tablet: 260 mg

Dosage
?Capsules, Tablets Chloroquine-resistant malaria.
Adults: 650 mg q 8 hr for at least 3 days (7 days in Southeast Asia) along with pyrimethamine, 25 mg b.i.d. for the first 3 days and sulfadiazine, 2 g/day for the first 5 days. There are two alternative regimens: (1) quinine, 650 mg q 8 hr for at least 3 days (7 days in Southeast Asia) along with a tetracycline, 250 mg q 6 hr for 10 days or (2) quinine, 650 mg q 8 hr for 3 days with sulfadoxine, 1.5 g and pyrimethamine, 75 mg as a single dose.
Chloroquine-sensitive malaria.
Adults: 600 mg q 8 hr for 5-7 days. Pediatric: 10 mg/kg q 8 hr for 5-7 days.
Nocturnal leg cramps.
Adults: 260-300 mg at bedtime.

Quinine sulfate Ratings

Overall Rating:

0.0

 

(based on 0 reviews)

Effectiveness:

Ease of Use:

Overall Satisfaction:

Reviewit

Reviews

Sure is quiet in here. You can write the first review of Quinine sulfate.